Comparison of Dual-immunosuppressive Therapy with a Voclosporin-based, Triple-immunosuppressive Regimen for Lupus Nephritis in the ALMS and AURORA 1 Studies (ACR Convergence 2023) - Sep 24, 2023 - Abstract #0782; Pres time: Nov 12, 2023; 02:15 PM - 02:25 PM; Location: Ballroom 20D; in person; "Background/Purpose: Dual-immunosuppressive regimens consisting of high-dose glucocorticoids and higher doses ( >2 g/day) of mycophenolate mofetil (MMF) are still frequently used for the initial management of active lupus nephritis (LN) despite the known serious and dose-dependent safety risks associated with both of these agents. Patients treated with voclosporin in combination with low-dose glucocorticoids and lower-dose MMF demonstrated an improved safety profile and earlier reductions in proteinuria compared to patients treated with high-dose glucocorticoids and higher doses of MMF. These findings affirm the KDIGO 2023 recommendation that a voclosporin-based, triple-immunotherapy regimen should be considered as an initial therapy in patients with active LN. M."
CNS Disorders • Gastrointestinal Disorder • Glomerulonephritis • Immunology • Inflammatory Arthritis • Lupus • Lupus Nephritis • Mental Retardation • Nephrology • Psychiatry • Renal Disease
|
|
Maria Dall'Era1; Ernie Yap2; Matt Truman2; Lucy Hodge2; Neil Solomons3
|